Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

GlobeNewswire Inc. • Jan 8, 2026 7:00am (New York) •By Na

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Entrada Therapeutics reported progress across its RNA-based therapeutic pipeline, with multiple clinical programs in development for Duchenne muscular dystrophy (DMD) and expansion into ocular diseases. The company expects to report data from ELEVATE-44-201 in Q2 2026 and ELEVATE-45-201 in mid-2026, initiate a Phase 1/2 study for ENTR-601-50 by end of 2026, and submit regulatory applications for ENTR-601-51 in 2026. Entrada selected ENTR-801 as its first clinical candidate for Usher syndrome type 2A treatment and plans to nominate a second ocular candidate in 2026. The company maintains cash runway into Q3 2027.

← Back to news Read Original Article

Insights

TRDA positive

Company demonstrated significant pipeline progress with multiple clinical programs advancing on schedule, FDA rare pediatric disease designation granted, expansion into new therapeutic area (ocular diseases), and adequate cash runway through Q3 2027. Multiple data readouts expected in 2026 represent key value inflection points.

Keywords

#RNA-based therapeutics #Duchenne muscular dystrophy #Usher syndrome #exon skipping #clinical trials #ocular diseases #neuromuscular diseases #Phase 1/2 studies #regulatory approval

Tickers

TRDA VRTX

← Prev: Faraday Future Unveils Ambitious FX Super One Roadmap

Next: Blue Star Families Welcomes New Advisory Board Members to Advance Military Family Initiatives →